A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan

Mika Mizuno, Masamichi Hiura, Fumitaka Kikkawa, Fumitaka Numa, Nobuo Yaegashi, Hisashi Narahara, Daisuke Aoki, Eizo Kimura, Hisamori Kato, Mototsugu Shimokawa, Toru Sugiyama, Toshiharu Kamura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective This study was performed to investigate the occurrence of and risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. Methods In total, 214 patients with gynecologic cancer who underwent highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC) were evaluated. We investigated the relationship between CINV and clinical factors and the accuracy of estimation of CINV by medical staff in the acute and late phases. Vomiting was evaluated in terms of frequency, and nausea was evaluated with a 100-mm visual analog scale on days 1 to 7. We also analyzed the risk factors and changes in CINV over time using a generalized linear mixed (GLM) model. Results The multivariate analysis revealed no significant risk factors for acute CINV. The independent risk factors for delayed nausea were a morning sickness history (odds ratio [OR], 2.687; 95% confidence interval [95% CI], 1.450-4.976; p = 0.0017), age (each 1-year increment) (OR, 0.97; 95% CI, 0.944-0.996; p = 0.0235), and HEC (OR, 2.134; 95% CI, 1.039-4.383; p = 0.0391). The GLM model demonstrated that the independent factors affecting nausea were significant morning sickness (p = 0.0101) and HEC (p = 0.0136). These data also showed more severe nausea from days 3 to 5, but the negative predictive value for estimation of delayed nausea by medical staff was 57.8%. Conclusion Our data suggest that improvement of preventive antiemetic administration is needed for patients with risk factors to manage delayed CINV caused by HEC and by MEC.

Original languageEnglish
Pages (from-to)559-564
Number of pages6
JournalGynecologic Oncology
Volume140
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Nausea
Vomiting
Observational Studies
Japan
Prospective Studies
Drug Therapy
Neoplasms
Morning Sickness
Medical Staff
Odds Ratio
Confidence Intervals
Linear Models
Antiemetics
Visual Analog Scale
Multivariate Analysis

Keywords

  • Antiemetics
  • Chemotherapy
  • Gynecologic cancer
  • Nausea
  • Vomiting

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan. / Mizuno, Mika; Hiura, Masamichi; Kikkawa, Fumitaka; Numa, Fumitaka; Yaegashi, Nobuo; Narahara, Hisashi; Aoki, Daisuke; Kimura, Eizo; Kato, Hisamori; Shimokawa, Mototsugu; Sugiyama, Toru; Kamura, Toshiharu.

In: Gynecologic Oncology, Vol. 140, No. 3, 01.03.2016, p. 559-564.

Research output: Contribution to journalArticle

Mizuno, M, Hiura, M, Kikkawa, F, Numa, F, Yaegashi, N, Narahara, H, Aoki, D, Kimura, E, Kato, H, Shimokawa, M, Sugiyama, T & Kamura, T 2016, 'A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan', Gynecologic Oncology, vol. 140, no. 3, pp. 559-564. https://doi.org/10.1016/j.ygyno.2015.12.029
Mizuno, Mika ; Hiura, Masamichi ; Kikkawa, Fumitaka ; Numa, Fumitaka ; Yaegashi, Nobuo ; Narahara, Hisashi ; Aoki, Daisuke ; Kimura, Eizo ; Kato, Hisamori ; Shimokawa, Mototsugu ; Sugiyama, Toru ; Kamura, Toshiharu. / A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan. In: Gynecologic Oncology. 2016 ; Vol. 140, No. 3. pp. 559-564.
@article{e3dfc1e668c940979d2ab53079667535,
title = "A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan",
abstract = "Objective This study was performed to investigate the occurrence of and risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. Methods In total, 214 patients with gynecologic cancer who underwent highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC) were evaluated. We investigated the relationship between CINV and clinical factors and the accuracy of estimation of CINV by medical staff in the acute and late phases. Vomiting was evaluated in terms of frequency, and nausea was evaluated with a 100-mm visual analog scale on days 1 to 7. We also analyzed the risk factors and changes in CINV over time using a generalized linear mixed (GLM) model. Results The multivariate analysis revealed no significant risk factors for acute CINV. The independent risk factors for delayed nausea were a morning sickness history (odds ratio [OR], 2.687; 95{\%} confidence interval [95{\%} CI], 1.450-4.976; p = 0.0017), age (each 1-year increment) (OR, 0.97; 95{\%} CI, 0.944-0.996; p = 0.0235), and HEC (OR, 2.134; 95{\%} CI, 1.039-4.383; p = 0.0391). The GLM model demonstrated that the independent factors affecting nausea were significant morning sickness (p = 0.0101) and HEC (p = 0.0136). These data also showed more severe nausea from days 3 to 5, but the negative predictive value for estimation of delayed nausea by medical staff was 57.8{\%}. Conclusion Our data suggest that improvement of preventive antiemetic administration is needed for patients with risk factors to manage delayed CINV caused by HEC and by MEC.",
keywords = "Antiemetics, Chemotherapy, Gynecologic cancer, Nausea, Vomiting",
author = "Mika Mizuno and Masamichi Hiura and Fumitaka Kikkawa and Fumitaka Numa and Nobuo Yaegashi and Hisashi Narahara and Daisuke Aoki and Eizo Kimura and Hisamori Kato and Mototsugu Shimokawa and Toru Sugiyama and Toshiharu Kamura",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.ygyno.2015.12.029",
language = "English",
volume = "140",
pages = "559--564",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan

AU - Mizuno, Mika

AU - Hiura, Masamichi

AU - Kikkawa, Fumitaka

AU - Numa, Fumitaka

AU - Yaegashi, Nobuo

AU - Narahara, Hisashi

AU - Aoki, Daisuke

AU - Kimura, Eizo

AU - Kato, Hisamori

AU - Shimokawa, Mototsugu

AU - Sugiyama, Toru

AU - Kamura, Toshiharu

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective This study was performed to investigate the occurrence of and risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. Methods In total, 214 patients with gynecologic cancer who underwent highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC) were evaluated. We investigated the relationship between CINV and clinical factors and the accuracy of estimation of CINV by medical staff in the acute and late phases. Vomiting was evaluated in terms of frequency, and nausea was evaluated with a 100-mm visual analog scale on days 1 to 7. We also analyzed the risk factors and changes in CINV over time using a generalized linear mixed (GLM) model. Results The multivariate analysis revealed no significant risk factors for acute CINV. The independent risk factors for delayed nausea were a morning sickness history (odds ratio [OR], 2.687; 95% confidence interval [95% CI], 1.450-4.976; p = 0.0017), age (each 1-year increment) (OR, 0.97; 95% CI, 0.944-0.996; p = 0.0235), and HEC (OR, 2.134; 95% CI, 1.039-4.383; p = 0.0391). The GLM model demonstrated that the independent factors affecting nausea were significant morning sickness (p = 0.0101) and HEC (p = 0.0136). These data also showed more severe nausea from days 3 to 5, but the negative predictive value for estimation of delayed nausea by medical staff was 57.8%. Conclusion Our data suggest that improvement of preventive antiemetic administration is needed for patients with risk factors to manage delayed CINV caused by HEC and by MEC.

AB - Objective This study was performed to investigate the occurrence of and risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. Methods In total, 214 patients with gynecologic cancer who underwent highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC) were evaluated. We investigated the relationship between CINV and clinical factors and the accuracy of estimation of CINV by medical staff in the acute and late phases. Vomiting was evaluated in terms of frequency, and nausea was evaluated with a 100-mm visual analog scale on days 1 to 7. We also analyzed the risk factors and changes in CINV over time using a generalized linear mixed (GLM) model. Results The multivariate analysis revealed no significant risk factors for acute CINV. The independent risk factors for delayed nausea were a morning sickness history (odds ratio [OR], 2.687; 95% confidence interval [95% CI], 1.450-4.976; p = 0.0017), age (each 1-year increment) (OR, 0.97; 95% CI, 0.944-0.996; p = 0.0235), and HEC (OR, 2.134; 95% CI, 1.039-4.383; p = 0.0391). The GLM model demonstrated that the independent factors affecting nausea were significant morning sickness (p = 0.0101) and HEC (p = 0.0136). These data also showed more severe nausea from days 3 to 5, but the negative predictive value for estimation of delayed nausea by medical staff was 57.8%. Conclusion Our data suggest that improvement of preventive antiemetic administration is needed for patients with risk factors to manage delayed CINV caused by HEC and by MEC.

KW - Antiemetics

KW - Chemotherapy

KW - Gynecologic cancer

KW - Nausea

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=84959487074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959487074&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.12.029

DO - 10.1016/j.ygyno.2015.12.029

M3 - Article

C2 - 26748216

AN - SCOPUS:84959487074

VL - 140

SP - 559

EP - 564

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -